Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 186 participants.
Also called NCT07531108
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 186 participants
- Sponsor
- Hawler Medical University
- Registry
-
NCT07531108
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Iraq
- Registry status
- Completed
Technical summary
Registry record NCT07531108. Non-randomized; no masking; primary purpose treatment. Start 2024-11-15 (actual); primary completion 2025-11-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Empagliflozin-Metformin
- Intervention (Drug)
- Sitagliptin-Metformin
- Intervention (Drug)
- Metformin
- Lead sponsor
- Hawler Medical University
Record details
- Record id
cardio:ct-nct07531108- Content hash
5479bc763b346b17d827447e9e1fb3f11bbcb122d38b9ab865a2f24a32001969